![]() |
![]() |
|
![]() |
| SMIP™ Drug Design | ||
|
SMIP drugs are highly-specific, single-chain polypeptides designed with optimized target binding and effector functions to overcome limitations of therapeutic antibodies and antibody alternatives. |
||
| Pipeline | ||
Trubion has multiple SMIP drugs in pre-clinical and clinical development. The company’s lead product, TRU-015, is in Phase 2 clinical development for the treatment of rheumatoid arthritis. |
||